Cincinnati · Montgomery · Edgewood, KY By appointment · Most insurance accepted
Contact
Request a Consultation

RegenLife Centers · Physician-led care

PRP for Hair Loss Cincinnati OH

How Platelet-Rich Plasma Regrows Hair

Published on November 16th, 2026

Caitlyn Benton
Written by
Caitlyn Benton
Dr. Zeeshan Tayeb
Reviewed and Approved by
Dr. Zeeshan Tayeb

The 41-year-old who has watched the part in her hair widen over four years, who bought the volumizing shampoos, tried the biotin supplements that produced no measurable change, applied the minoxidil foam until the flaking and irritation made her stop, and sat through a primary care visit where her labs came back "within normal limits" and she was told that female hair loss is complicated and sometimes just happens, who never learned that a treatment requiring nothing but her own blood, no surgery, no daily pharmaceutical application, and no recovery period exists, is available in Cincinnati, and has been evaluated in more than 40 randomized controlled trials: this patient has not exhausted the options available to her. She has exhausted the options that were offered to her, which is not the same thing. The man whose barber started angling the clippers differently three years ago to cover what isn't growing back anymore, who takes finasteride because his dermatologist said it was the first line and has noticed that his hairline is still receding even if more slowly, who does not know that an office-based procedure using concentrated growth factors drawn from his own blood can stimulate dormant follicles by directly targeting the biological cascade that androgenic alopecia is suppressing: this patient is also not at the end of the road. He is at the beginning of a conversation that standard hair loss care rarely initiates.

PRP for hair loss, platelet-rich plasma injected into thinning areas of the scalp to deliver concentrated growth factors directly to miniaturizing follicles, addresses the cellular biology of androgenetic alopecia in a way that topical treatments and oral medications only partially reach, by placing biologically active signals at the exact site where follicular dormancy and miniaturization are occurring. At RegenLife Centers for Integrative Pain & Weight Management, PRP for hair loss in Cincinnati OH is offered within a comprehensive evaluation that identifies the hormonal, inflammatory, nutritional, and thyroid-related drivers of hair thinning before any injection protocol is selected, because the patient whose hair is thinning due to testosterone dysregulation is a clinically different presentation than the one whose pattern reflects low ferritin, chronic inflammation, or hypothyroidism.

A healthcare professional carefully administers an injection to a patient in a clinical settingA healthcare professional carefully administers an injection to a patient in a clinical setting

Key Takeaways

  • A 2025 systematic review and meta-analysis of 43 randomized controlled trials involving 1,877 participants confirmed that activated PRP significantly increases hair density and reduces hair loss compared to placebo, with hair density improvements documented at up to 42% in patients receiving high-platelet-concentration PRP
  • PRP works by delivering concentrated platelet-derived growth factors: including PDGF, VEGF, IGF-1, TGF-β, and EGF, directly to follicles in miniaturization or dormancy, reactivating the Wnt/β-catenin signaling pathway that androgenic hormones systematically suppress in susceptible follicles
  • Most patients follow an initial series of 3 monthly sessions, with visible new growth appearing at 2–3 months and continued improvement through 6 months, maintained through 4–6 month booster sessions: and combination with microneedling or topical minoxidil significantly amplifies outcomes beyond PRP alone
  • PRP for hair loss has its strongest evidence base in androgenetic alopecia: male and female pattern hair loss, with 70–80% of appropriate candidates experiencing meaningful improvement in hair count, shaft thickness, and density

Understanding PRP for Hair Loss: What Platelet-Rich Plasma Actually Does

What Platelet-Rich Plasma Contains

Platelets are the component of blood best known for wound clotting, but they carry a payload that the clotting function only partially reveals. Embedded within each platelet are hundreds of growth factor proteins stored in alpha granules: platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), and fibroblast growth factors (FGF2 and FGF10), among others. When platelets are activated, by tissue injury, by thrombin during normal clotting, or by the activation agents used in PRP preparation. They degranulate, releasing this growth factor payload into the surrounding tissue.

PRP is prepared by drawing a small volume of the patient's blood, spinning it in a centrifuge to separate its components by density, and extracting the platelet-rich fraction, which can contain three to five times the platelet concentration of whole blood. This concentrated suspension is then injected into the scalp at the level of the dermal papilla, the highly vascularized structure at the base of each hair follicle that controls the follicle's activity, cycling, and survival. The growth factors released at that location send direct biological signals to the cells responsible for hair production, not indirectly through systemic circulation, but locally, at the structure that has been losing the signals it needs.

Why Hair Follicles Respond to PRP's Growth Factor Signals

The hair follicle is not a passive tube from which hair extrudes. It is a dynamic, cycling structure that moves through three defined phases: anagen (active growth, lasting 2–7 years in healthy follicles), catagen (regression, 2–3 weeks), and telogen (rest, 3 months). In androgenetic alopecia, the anagen phase shortens progressively under the influence of dihydrotestosterone (DHT), the follicle miniaturizes over successive cycles, and the hair it produces becomes finer, shorter, and less pigmented until the follicle ceases productive activity altogether.

The growth factors in PRP directly counteract this process. VEGF stimulates angiogenesis around the follicle's dermal papilla, building the vascular supply that a shrinking follicle progressively loses. IGF-1 and FGF activate Wnt/β-catenin signaling in bulge stem cells, the reservoir from which the follicle regenerates at the start of each anagen phase. EGF maintains keratinocyte proliferation and protects follicular cells from immune-mediated inflammation. The net effect of this growth factor cascade is a prolonged anagen phase, increased follicle caliber, and the reactivation of follicles that have entered extended dormancy, changes that translate into measurable increases in hair count, density, and shaft diameter.


The Biology of Androgenetic Alopecia and Why PRP Addresses It at the Source

Healthcare professional holding blood vials next to a laboratory centrifuge in a clinical settingHealthcare professional holding blood vials next to a laboratory centrifuge in a clinical setting

What DHT Does to Genetically Susceptible Follicles

Androgenetic alopecia, the most common cause of hair loss in both sexes, affecting approximately 50% of men by age 50 and up to 40% of women by menopause, is driven by a specific interaction between DHT and androgen receptors in scalp follicles carrying genetic sensitivity to androgenic signaling. When DHT binds androgen receptors in the dermal papilla of susceptible follicles, it triggers a downstream consequence that extends beyond the follicle itself: the androgen receptor complex recruits β-catenin as a coactivator to stimulate expression of Dickkopf-1 (DKK1), a potent inhibitor of the Wnt/β-catenin signaling pathway that hair follicle cycling depends on. In plain terms: DHT doesn't just shrink the follicle directly. It turns off the molecular switch the follicle uses to tell itself to grow.

This is why finasteride and minoxidil, the two FDA-approved medications for androgenetic alopecia, work partially but incompletely. Finasteride blocks the conversion of testosterone to DHT but does not directly re-activate the Wnt/β-catenin pathway that DHT suppression has been depleting. Minoxidil prolongs the anagen phase through vasodilatory mechanisms but does not address the signaling deficit at the dermal papilla. Neither treatment delivers growth factors locally to the follicle or directly restores the cellular signaling that miniaturization has progressively attenuated.

The Wnt/β-Catenin Pathway: The Target PRP Directly Restores

PRP's growth factors, particularly IGF-1, FGF, and VEGF, directly upregulate Wnt/β-catenin signaling in both the bulge stem cell niche and the dermal papilla, counteracting the DKK1-mediated suppression that DHT has produced. This is not a theoretical mechanism inferred from in vitro data: clinical studies confirm that PRP produces measurable increases in hair count, density, and diameter in human patients with androgenetic alopecia, across dozens of randomized controlled trials with outcomes consistent with Wnt/β-catenin reactivation. The fact that PRP operates through a pathway distinct from, and complementary to, finasteride and minoxidil is the mechanistic basis for why combination therapy consistently outperforms any single treatment.


How PRP Is Prepared and Administered: The Three-Step Process

Blood Draw, Centrifugation, and Injection

The PRP preparation process begins with drawing 20–60 mL of the patient's venous blood, less than a standard blood donation, into collection tubes containing an anticoagulant. The tubes are placed in a calibrated centrifuge and spun at specific speeds and durations designed to separate blood components by density: red blood cells settle to the bottom, a platelet-poor plasma layer floats at the top, and the platelet-rich plasma fraction concentrates at the interface between them. The PRP fraction is extracted, optionally activated with a small volume of calcium chloride or thrombin to trigger immediate degranulation, and loaded into syringes for injection.

The entire process from blood draw to injection takes approximately 30–45 minutes within a single clinical visit. The platelet concentration in the extracted PRP can reach three to five times the baseline platelet count in whole blood, a concentration sufficient to produce the growth factor payload that clinical studies have documented as effective. One study documented a 42% increase in hair density in patients receiving PRP with platelet counts exceeding 10 lakh/mm³, highlighting that preparation protocol and final platelet concentration are clinically meaningful variables rather than interchangeable details.

Delivery Methods: Intradermal Injection vs. Microneedling

The standard delivery method for scalp PRP is point-by-point intradermal injection at 1 cm intervals across the thinning area, a grid pattern that distributes the growth factor payload across the dermal papilla of multiple follicles simultaneously. Topical anesthetic cream applied 30–45 minutes before the procedure substantially reduces injection discomfort; most patients describe the procedure as tolerable, with a brief burning sensation at each injection site that resolves within seconds.

A 2021 study found that automated microneedling combined with PRP delivery produced greater clinical improvements than syringe-based intradermal injection alone, a finding with practical implications for treatment planning. Microneedling creates controlled micro-channels in the dermis that enhance PRP penetration to the follicle level while independently stimulating growth factor release through the wound-healing response, creating a synergistic effect that injection alone does not replicate. At clinics equipped for both delivery methods, the combination is increasingly the standard approach for patients whose follicle depth and scalp anatomy make it appropriate.


What the Evidence Shows: Clinical Results for PRP Hair Restoration

A woman brushing her healthy hair, showing texture and thicknessA woman brushing her healthy hair, showing texture and thickness

Randomized Controlled Trial Outcomes

The evidence base for PRP in androgenetic alopecia has grown substantially over the past decade. A 2025 systematic review and meta-analysis published in Dermatology and Therapy, encompassing 43 randomized controlled trials and 1,877 participants, confirmed that activated PRP significantly increases hair density and minimizes recurrence compared to placebo. An 11-trial meta-analysis published in PMC in 2025, involving 684 participants across studies from January 2020 to May 2024, concluded that "PRP significantly enhances hair density and diameter compared to placebo treatments," with individual studies reporting outcomes including a 91.4% patient improvement rate (Afzal et al.) and statistically significant increases in hair count observed across measurement time points at 3, 6, and 9 months.

Patient satisfaction data across trials ranges from 45.8% to 95%, a spread that reflects not inconsistency in PRP's biology but inconsistency in preparation protocols, specifically centrifugation methods, platelet activation, final concentration variability, and injection technique. The clinical implication is that PRP outcomes depend substantially on how the treatment is prepared and administered, not merely on whether it is used. Clinics using standardized, calibrated preparation protocols consistently report outcomes at the upper end of published ranges. It is also worth noting that a small number of trials, notably Gressenberger et al. (2020), found no statistically significant difference versus placebo, a finding that reinforces the protocol-dependence of results and the importance of the preparation variables the majority of positive studies controlled for.

Combination Therapy: Where PRP Consistently Outperforms Monotherapy

The clearest consistent finding across the PRP hair loss literature is that combination therapy outperforms PRP alone. A meta-analysis of randomized trials found that PRP combined with topical minoxidil significantly improved hair growth outcomes compared to either treatment alone. A study by Singh et al. found that PRP plus minoxidil produced significantly greater hair density improvement than minoxidil monotherapy. Pakhomova et al. confirmed combined treatment increased hair growth more than either monotherapy, and notably found that PRP alone was more effective than minoxidil alone for promoting terminal hair growth, a finding that positions PRP not as an adjunct to medication but as a primary intervention with additive value when combined.

For patients already using finasteride or minoxidil whose results have plateaued, whose medication is stabilizing loss without producing meaningful regrowth, PRP addresses the complementary biological target that their medication's mechanism does not reach, providing the growth factor stimulation at the follicle level that pharmaceutical treatment alone cannot deliver.


Who Is a Good Candidate for PRP Hair Restoration

The Presentations with the Strongest Evidence

PRP for hair loss has its strongest evidence base in androgenetic alopecia, male and female pattern hair loss, across all stages from early diffuse thinning to moderate pattern baldness. The key variable for candidate selection is follicle viability: PRP stimulates dormant and miniaturized follicles, but follicles that have been absent for years and replaced by scar tissue cannot be reactivated by any growth factor intervention. Patients in the early to moderate stages of androgenetic alopecia, where the follicle is miniaturized and producing finer hair but the follicle unit itself is still present, are the biologically appropriate candidates for whom clinical evidence is strongest.

PRP also shows clinical promise in alopecia areata, the autoimmune condition characterized by patchy hair loss, through its immune-modulating effects: reducing the local inflammatory response that the immune system is generating against follicular antigens. Evidence for alopecia areata remains smaller in volume than for androgenetic alopecia, but the mechanistic rationale is coherent and clinical series data is encouraging. Female pattern hair loss, which is frequently under-diagnosed and under-treated, often attributed to stress or labeled as "hormonal" without further investigation, responds to PRP through the same biological mechanisms as male pattern baldness, and several RCTs have confirmed its effectiveness specifically in women.

Who PRP May Not Be Right For

PRP is not appropriate for patients with scarring alopecia, conditions including lichen planopilaris, frontal fibrosing alopecia, and discoid lupus erythematosus, in which the hair follicle is destroyed by inflammatory scarring and replaced by fibrous tissue. No growth factor intervention can restore follicles where the follicular unit no longer exists. PRP is also contraindicated in patients with platelet dysfunction syndrome, active scalp infection, certain blood or clotting disorders, and active cancer, conditions in which delivering concentrated growth factors into proliferating or inflamed tissue creates risks that outweigh the treatment's benefits.

Patients whose hair loss has a systemic root cause, hypothyroidism, iron deficiency anemia, severe nutritional depletion, or hormonal imbalance, are best served by addressing the systemic driver first. PRP injected into a scalp where thyroid deficiency is suppressing the anagen phase, or where ferritin levels are insufficient for follicle matrix cell division, operates in a suboptimal biological environment. The comprehensive evaluation that precedes treatment at RegenLife is designed to identify these systemic contributors before any injection protocol is selected.


Timeline, Sessions, and What to Expect from PRP Hair Treatment

The Standard Treatment Schedule

The most widely used initial PRP hair loss protocol, and the one most consistently used across published clinical trials, is three sessions spaced four weeks apart, followed by reassessment at six months. Most patients are advised to plan for 3–4 initial monthly sessions to establish the biological response, as the growth factor stimulation is cumulative: each session builds on the dermal papilla activation and angiogenesis initiated by the session before it. After the initial series, maintenance sessions every four to six months sustain the anagen-phase extension and growth factor environment that treatment has established.

The procedure itself takes 30–45 minutes per visit from blood draw through injection. Minor scalp redness and swelling at injection sites typically resolves within 24–48 hours. A transient increase in shedding, telogen effluvium, in the weeks following early sessions is a recognized response reflecting the follicle cycling that growth factor activation induces: follicles entering a new anagen phase shed the telogen-phase hairs they were holding, a process that precedes visible regrowth by 6–8 weeks. Patients who understand this response avoid discontinuing treatment at exactly the moment it is beginning to work.

When You Will See Results: How Long They Last

Initial new hair growth from PRP therapy typically becomes visible at 2–3 months after the first treatment session, with hair count and density continuing to improve through the 6-month mark as follicles complete their transition into productive anagen phase. Full results are generally assessed at six months following the initial series. Results from PRP hair restoration, when maintained with appropriate booster sessions, have been documented to last 12–18 months; without maintenance, gradual return of hair thinning typically begins within 6–12 months as the androgenic environment resumes its suppressive influence on follicular cycling.

PRP is not a cure for androgenetic alopecia in the same sense that finasteride is not a cure: both treatments address the condition while administered and require ongoing maintenance to preserve their biological effect. For patients who have experienced meaningful regrowth and density improvement, the maintenance commitment, two sessions per year, is a practical investment compared to the alternative of allowing the improvement to gradually reverse.


The Integrated Evaluation at RegenLife: PRP for Hair Loss Cincinnati OH

Woman receives a cosmetic injection in a clinical settingWoman receives a cosmetic injection in a clinical setting

Hormonal and Systemic Context That Determines Treatment Response

Comprehensive PRP hair restoration at RegenLife begins with an evaluation that looks at the systemic environment in which PRP is operating, not because PRP requires a perfect biological substrate to work, but because the patient with unaddressed testosterone dysregulation, low ferritin, or subclinical hypothyroidism achieves a fraction of the response that an optimized patient achieves. The hormone therapy and diagnostic services at RegenLife characterize the hormonal and metabolic status that independently determines follicle cycling before the first injection is placed.

The patient with low testosterone, male or female, whose androgen receptor signaling is dysregulated across the scalp is a different clinical substrate for PRP than the patient whose androgens are balanced and whose hair loss reflects a purely local follicular sensitivity pattern. Testosterone replacement therapy and bioidentical hormone therapy address the systemic hormonal environment that scalp injections cannot reach, and in patients where hormonal optimization is indicated, restoring hormonal balance before or alongside PRP produces outcomes that injection alone cannot replicate. For women whose hair thinning is driven by the estrogen decline of menopause, menopause hormone therapy addresses the systemic hormonal environment while PRP targets the follicular response locally.

How PRP Integrates with Regenerative and Lifestyle Medicine

The same biological principles underlying platelet-rich plasma therapy for joints and soft tissue, growth factor delivery, angiogenesis stimulation, tissue repair signaling, apply directly to hair follicle restoration. Patients receiving PRP for musculoskeletal conditions at RegenLife who have noticed concurrent improvement in hair density are observing the same growth factor mechanism operating across different tissue targets. The lifestyle medicine protocols at RegenLife address the nutritional, inflammatory, and metabolic drivers that independently impair follicle function: chronic inflammation elevates the DHT sensitivity of scalp follicles; insulin resistance impairs the growth factor receptor signaling that PRP is designed to activate; gut health and nutrient absorption status determine whether the cofactors for matrix cell division and keratin synthesis are available at the follicle level where PRP's growth signals arrive.

The diagnostic services evaluation at RegenLife includes the micronutrient assessment, thyroid panel, and inflammatory marker profile that characterize the systemic contributors to hair loss before any injection protocol is selected, because PRP delivered into a scalp operating under systemic nutritional depletion or uncontrolled thyroid dysfunction is not the same biological intervention as PRP delivered into an optimized biological environment. For patients whose hair loss is multifactorial, combining androgenetic pattern loss with systemic contributors, addressing each driver systematically produces the compounding benefit that targeting follicular biology alone cannot.


Contact RegenLife Centers to schedule an evaluation or ask which service fits your needs.


Frequently Asked Questions

Find answers to common questions

Ready to Learn More?

To learn more and to find out if you might be a good candidate at RegenLife, schedule a consultation with our team today.

About the Author

Caitlyn Benton

Caitlyn Benton, Research Manager at RegenLife

As Research Manager, Caitlyn Benton oversees the strategic planning and execution of clinical research projects, ensuring all studies adhere to the highest regulatory and ethical standards. With expertise in protocol development and data monitoring, she coordinates multidisciplinary teams to ensure the integrity of our clinical research programs and the accuracy of the insights shared with our patients.

Reviewed and Approved by

Dr. Zeeshan Tayeb

Dr. Zeeshan Tayeb, Medical Director at RegenLife

Interventional Spine, Pain, and Sports Medicine Dr. Zeeshan Tayeb, MD is board-certified in Pain Medicine and Physical Medicine & Rehabilitation, with specialized fellowship training in interventional spine, pain, and sports medicine. He sees patients at Pain Specialists of Cincinnati/RegenLife in Cincinnati, Ohio. Dr. Tayeb's background in physical medicine and rehabilitation has provided the foundation for his comprehensive approach to treating the whole person. Dr. Tayeb has done extensive training and education in both functional and regenerative medicine and specializes in state-of-the-art treatments, including laser therapies, PRP and stem-cell injections, and nutritional and hormonal optimization.

Disclaimer:

As a service to our readers, RegenLife provides access to our library of archived content. Please note the date of last review or update on all articles.

No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Stay Updated With Our Latest News

Check back regularly for new articles and updates about pain management treatments, practice news, and health tips from our team of specialists.

Get In Touch

Same-week consults. Real follow-through.

Tell us what's going on. A coordinator will follow up during office hours to help book your visit.

Request a consultation

Choose the clinic that works for you.

Most new patients can be seen within the same week.

Cincinnati

3328 Westbourne Dr

Cincinnati, OH 45248

(513) 922-2204

Edgewood

162 Barnwood Dr

Edgewood, KY 41017

(859) 331-4159

Montgomery

9989 Montgomery Rd

Montgomery, OH 45242

(513) 922-2204

We accept most major insurance plans

RequestCallDirections